Tanreqing Injection On Experimental Clinical Studies Of Influenza

Background Influenza is caused by the influenza virus an acute febrile respiratory infections, referred to as "flu. " In Chinese literature the equivalent of "the line"disease, "when the line of a cold, ""when the gas, ""pestilence" and other areas. Influenza virus is the causative agent of influenza, its main clinical features of acute high fever, body aches, fatigue, and mild respiratory symptoms. Specificity of influenza virus nucleoprotein is usually divided accordingto A, B, C-â…¢. Influenza virus gene rearrangement prone antigen induced change, it is prone to periodic antigenic variation, new subspecies and varieties, causing a worldwide pandemic, a serious threat to human health. With the social and economic development, the world becomes a global village, influenza outbreaks have tended to threaten global human security. Countries in the world history of influenza are influenza pandemic occurred, hundreds of millions of deaths. A recent pandemic occurred in March 2009, Mexico outbreak "swine flu"epidemic, and quickly spread worldwide. World Health Organization (WHO) this initial influenza known as the "swine flu" will be renamed the "Influenza H1N1 flu.Objective 61 cases of influenza patients through a randomized controlled study, patients were observed after admission mean fever clearance time, the virus nucleic acid clearance time and the time of influenza-like symptoms and other indicators of Tanreqing injection compared with the Tamiflu treatment of influenza A virus Clinical efficacy. Tanreqing injection to compare the addition and subtraction with oseltamivir phosphate treatment efficacy of influenza.Methods A randomized, positive control of clinical trial design, the subjects for the July 10,2010 ~ August 17, Shenzhen Hospital of respiratory, emergency department,61 cases of fever clinics outpatient influenza cases were divided into treatment Group and control group,31 patients were randomly divided into treatment and control group of 30 patients, the treatment group to Tanreqing intravenous injection, oral administration of Tamiflu to the control group. Tanreqing treatment group to intravenous injection; control group with oral administration of oseltamivir phosphate capsules (Tamiflu),75mg/time, twice a day. Children's doses based on body weight-taking doses of the table Results The two groups was no significant difference in the general information, the statistically comparable (P> 0.05).61 cases of influenza A randomized controlled clinical trials in patients showed Tanreqing injection group compared with Tamiflu, the virus RNA negative rate was 22.58% 40.00% days, no significant difference (P> 0.05). The mean fever clearance time were: Tanreqing injection group 29.9 hours,27.8 hours Tamiflu phase, no significant difference (P> 0.05). Flu-like symptoms including cough, sore throat, nasal congestion/runny nose, fatigue and other lost time compared to the time the symptoms disappeared, compared two groups, the statistical analysis was no significant difference (P> 0.05).Conclusion According to the clinical observations, the analysis concluded that:the treatment group compared with the control group, the viral nucleic acid clearance time, mean fever clearance time and the time of influenza-like symptoms were associated with Tamiflu group of three very, indicating that the two groups Drug efficacy close.